Relmada Therapeutics (RLMD) Cost of Revenue (2012 - 2026)
Relmada Therapeutics (RLMD) reported Cost of Revenue of $2.8 million for Q1 2026, up 1689.33% year-over-year from $155600.0 in Q1 2025, and up 9.5% on a QoQ basis from $2.5 million in Q4 2025.
Relmada Therapeutics (RLMD) has 5 years of Cost of Revenue data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Cost of Revenue rose 1689.33% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (up 330.65% YoY) and the FY2025 annual result came in at $3.5 million, up 125.33% from the prior year.
- Cost of Revenue advanced to $2.8 million in Q1 2026 per RLMD's latest filing, from $2.5 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $2.8 million in Q1 2026 and bottomed at $81600.0 in Q2 2025.
- The 3-year median for Cost of Revenue is $301400.0 (2024), against an average of $875944.4.
- The widest annual swing landed in 2025, when Cost of Revenue tumbled 88.03%; it then jumped 1689.33% in 2026.
- Tracing RLMD's Cost of Revenue over 3 years: stood at $292000.0 in 2024, then soared by 770.79% to $2.5 million in 2025, then increased by 9.5% to $2.8 million in 2026.
- Per Business Quant, the three latest RLMD Cost of Revenue figures stand at $2.8 million (Q1 2026), $2.5 million (Q4 2025), and $752000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 2.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.78 Mn |
| Mar 31, 2026 | 2.78 Mn |
| Dec 31, 2025 | 2.54 Mn |
| Dec 31, 2025 | 2.54 Mn |
| Sep 30, 2025 | 752,000.00 |
| Sep 30, 2025 | 752,000.00 |
| Jun 30, 2025 | 81,600.00 |
| Jun 30, 2025 | 81,600.00 |
| Mar 31, 2025 | 155,600.00 |
| Mar 31, 2025 | 155,600.00 |
| Dec 31, 2024 | 292,000.00 |
| Dec 31, 2024 | 292,000.00 |
| Sep 30, 2024 | 301,400.00 |
| Sep 30, 2024 | 301,400.00 |
| Jun 30, 2024 | 681,500.00 |
| Jun 30, 2024 | 681,500.00 |
| Mar 31, 2024 | 292,500.00 |
| Mar 31, 2024 | 292,500.00 |
| Nov 30, 2013 | 1,686.00 |
| Nov 30, 2013 | 1,686.00 |
| May 31, 2013 | 322.00 |
| May 31, 2013 | 322.00 |
| Feb 28, 2013 | 1,864.00 |
| Feb 28, 2013 | 1,864.00 |
| Nov 30, 2012 | 1,850.00 |
| Nov 30, 2012 | 1,850.00 |
| Aug 31, 2012 | 998.00 |
| Aug 31, 2012 | 998.00 |
| May 31, 2012 | 292.00 |
| May 31, 2012 | 292.00 |